SUMMARY Changes in coronary arterial size due to ergonovine maleate are described and quantitated in 90 patients -18 with typical angina pectoris, 56 with atypical chest pain, nine with variant angina pectoris, and seven heart transplant (allograft) recipients. We observed two angiographic changes in the diameter of coronary arteries: 1) spasm, which was characterized by occlusion or marked (>85%) focal or diffuse vessel narrowing, or 2) relatively mild and diffuse vessel narrowing, which was interpreted as the normal pharmacologic response to the drug. Serial bolus injections of 0.05 mg, 0.10 mg and 0.25 mg of ergonovine maleate produced diffuse narrowing of the diameter of coronary arteries of 10 ± 1.5%, 16 ± 1.4% and 20 ± 1.3% (mean ± SEM), respectively, in the 72 patients with anginal syndromes who did not develop coronary spasm. The degree of coronary arterial narrowing was the same in heart transplant recipients and in patients with normally innervated hearts who did not develop coronary spasm. We believe the normal pharmacologic response to ergonovine maleate was due to a direct vasoconstrictor action of the drug; this action was independent of neural control extrinsic to the heart. CORONARY ARTERIAL SPASM is recognized as a cause of angina pectoris. In attempts to identify patients with this condition, various pharmacologic agents, including methacholine," 2 epinephrine,2 propranolol,2 and ergonovine maleate (EM),3 have been used to provoke coronary vasospasm during coronary arteriography. EM has been shown to induce coronary artery spasm at sites where spontaneous spasm was observed3' 5, 8 and vasospastic coronary artery disease has been demonstrated during coronary angiography by administering this drug. In this study we describe and quantitate the changes in coronary arterial diameter produced by EM when given to patients with various anginal syndromes. In addition, EM was given to heart transplant (allograft) recipients in an attempt to define the mechanism by which this drug affects coronary arterial size. would be given a drug that produced marked coronary artery narrowing which appeared to explain the cause of chest pain in some patients. Patients were told that we expected the results of the study to yield information that would be helpful in their medical treatment. The 90 patients studied included 47 men and 43 women ranging in age from 25-75 years (mean age 48 years). Eighty-three patients were given EM to determine if their anginal syndromes were related to coronary artery spasm. Eighteen of these 83 had typical angina pectoris produced by exercise and relieved by rest or nitrites. Fitly-six patients had chest pain that was not predictably related to stress or relieved by rest or nitrites, and at the time of study we did not know if their pain was cardiac in origin. Nine patients had variant angina pectoris, characterized by nonexertional chest pain that frequently occurred at night and was accompanied by ST-segment elevation. EM was also given to seven clinically stable heart transplant (allograft) recipients who were studied at the time of yearly coronary arteriography.
CORONARY ARTERIAL SPASM is recognized as a cause of angina pectoris. In attempts to identify patients with this condition, various pharmacologic agents, including methacholine," 2 epinephrine,2 propranolol,2 and ergonovine maleate (EM), 3 have been used to provoke coronary vasospasm during coronary arteriography. EM has been shown to induce coronary artery spasm at sites where spontaneous spasm was observed3 ' 5, 8 and vasospastic coronary artery disease has been demonstrated during coronary angiography by administering this drug. In this study we describe and quantitate the changes in coronary arterial diameter produced by EM when given to patients with various anginal syndromes. In addition, EM was given to heart transplant (allograft) recipients in an attempt to define the mechanism by which this drug affects coronary arterial size.
Materials and Methods
We studied 90 patients who received EM (Ergotrate Maleate, Eli Lilly & Co) after left ventriculography and coronary arteriography, using the Judkins technique, at Stanford University Hospital during [1975] [1976] [1977] . The administration of EM to induce coronary artery spasm has been approved by the Stanford Medical Committee on the Use of Human Subjects in Research. Patients with chest pain were selected for study if coronary artery spasm was a consideration clinically or if coronary angiography demonstrated arterial narrowing which was thought to be insufficient to account for their pain. They were told that they would be given a drug that produced marked coronary artery narrowing which appeared to explain the cause of chest pain in some patients. Patients were told that we expected the results of the study to yield information that would be helpful in their medical treatment.
The 90 patients studied included 47 men and 43 women ranging in age from 25-75 years (mean age 48 years). Eighty-three patients were given EM to determine if their anginal syndromes were related to coronary artery spasm. Eighteen of these 83 had typical angina pectoris produced by exercise and relieved by rest or nitrites. Fitly-six patients had chest pain that was not predictably related to stress or relieved by rest or nitrites, and at the time of study we did not know if their pain was cardiac in origin. Nine patients had variant angina pectoris, characterized by nonexertional chest pain that frequently occurred at night and was accompanied by ST-segment elevation. EM was also given to seven clinically stable heart transplant (allograft) recipients who were studied at the time of yearly coronary arteriography.
The 83 patients with anginal syndromes had coronary arterial narrowing of varying degrees demonstrated before the administration of EM. Forty-five patients, seven with typical angina pectoris and 38 with atypical chest pain, had no coronary arterial narrowing. Ten patients, including two with typical angina pectoris, five with atypical chest pain, and three with variant angina pectoris, had >0 and <50% narrowing of the diameter of the left anterior descending, circumflex and/or right coronary artery. Twenty-eight patients, nine with typical angina pectoris, 13 with atypical chest pain, and six with variant angina pectoris, had .50% narrowing of the diameter of one or more of these major coronary arteries. None of the heart transplant recipients had coronary arterial narrowing.
Nitrates and atropine were withheld before coronary angiography. There was continuous electrocardiographic monitoring and standard 12-lead ECGs were obtained at appropriate times during the ERGONOVINE AND CORONARY SIZE/Cipriano et al.
procedure. Sublingual and intravenous nitroglycerin (0.40 mg) was available for administration. EM was given in intravenous bolus injections after left ventriculography and coronary angiography. A total of 0.40 mg of EM was given in incremental doses of 0.05, 0.10 and 0.25 mg. We gave an additional bolus injection of 0.40 mg of EM (for a total dose of 0.80 mg EM) to five patients who did not develop coronary artery spasm after the initial 0.40 mg of EM. Four of these patients had atypical chest pain with no coronary artery narrowing, and one patient had variant angina pectoris with 50% diameter narrowing of the mid-left anterior descending and 60% diameter narrowing of the mid-right coronary artery. If electrocardiographic ST-segment shifts suggestive of myocardial ischemia were observed during spontaneous angina pectoris before coronary arteriography, the coronary arterial circulation (i.e., left or right coronary artery) which supplied the ischemic region of myocardium was studied during the initial administration of the drug. Coronary arteriography was performed immediately if the patient developed chest pain or electrocardiographic changes of myocardial ischemia caused by the administration of EM. Sublingual nitroglycerin was given once coronary spasm was demonstrated by angiography; therefore, with the Judkins technique, we were unaware of simultaneous changes in the diameter of the opposite coronary artery. In the absence of symptoms or electrocardiographic changes of myocardial ischemia, coronary arteriography was routinely done 3 minutes after each injection of the drug. After the total dose of EM was given and one coronary arterial system had been studied, arteriography of the other coronary arterial system was performed without giving more EM.
The diameters of the proximal, middle and distal third of the right, left anterior descending and circumflex coronary arteries were measured with calipers from 35 mm coronary cineangiograms which were projected on a 9" X 12" screen. Serial measurements were made at one site in each of these coronary artery segments. The measurements were made at enddiastole and in the same projection, before giving EM and after each injection of the drug. Anatomic features such as branch arteries and irregularities in the lumen of vessels served as references which allowed serial measurements of coronary artery diameters to be made at the same site. Segments of vessels that appeared to be normal angiographically were measured; measurements were not made at the origins of branch arteries or at sites of atherosclerotic narrowing. Reproducible measurements at 0.5 mm intervals could be obtained using this technique. The diameter of the coronary artery catheter was used as a standard of reference for determining the true size of coronary arteries, and alterations in coronary artery diameter size were calculated in millimeters and percent change in the size of the vessel before the administration of EM.
The data were analyzed to assess changes in the diameter of the proximal, middle and distal third of the right, left anterior descending, and circumflex coronary arteries after each injection of EM in patients with anginal syndromes who did not develop coronary arterial spasm. The following model for the analysis of variance gave a good fit for the data from these 72 patients:
yijkl =i + ai + fj + 'Yk + 61 + kjk + 11k1 + errorijkl
The dependent variable in this model is yijkl, in which i indexes patients, j indexes EM doses, k indexes coronary artery segments and I indexes coronary arteries. Measurements of coronary artery diameters from coronary angiograms were converted to the true size of these vessels by dividing the diameter of the coronary artery by the diameter of the coronary artery catheter. For the statistical analysis of variance, the measurements were converted to their natural logarithm. Therefore, in this model, y is the natural logarithm of the true size of the diameter of the coronary artery. We were primarily interested in determining the effects of doses of EM upon changes in coronary arterial diameter; however, it was important to consider factors which accounted for some of the variability within the data that was not related to EM. In the above model ,u is the grand mean or the average coronary artery diameter for these 72 patients; ai is the main effect for patient i or a factor which accounts for individual variation in average coronary arterial size; #j is the main effect for dose j (and the primary variable of interest) or the change in coronary arterial size that is due to the dose of EM; the y and 6 are main effects for factors that are accounted for by variations within the different coronary arteries (right, left anterior descending or circumflex) and coronary artery segments (proximal, mid or distal). The X and ?7 are interaction terms which account for a relationship between dose of EM and coronary artery (O) and dose of EM and coronary artery segment (i7), since it was possible that different coronary arteries or coronary arterial segments might react differently to EM. The "error" term in the model is equivalent to the unexplained variability in the data which has not been accounted for by the other parts of the model. This term would include errors in measurement and factors which were not considered.
Differences in response to EM between groups of patients were analyzed in an expanded model. The change in diameter of coronary arteries to cumulative doses of 0.05 mg, 0.15 mg and 0.40 mg of EM was determined for the groups of patients with typical angina pectoris and atypical chest pain in whom EM did not provoke coronary spasm, and the group of heart transplant recipients. To for the possibility that groups of patients with typical angina pectoris and atypical chest pain or heart transplant recipients might react differently to EM. The null hypothesis of no difference between pairs of these groups of patients, that is, (jj = 0, was tested using standard F tests.
Results
We observed two angiographic changes in the diameter of coronary arteries resulting from EM. One change, which we call coronary arterial spasm, was characterized by either focal or diffuse narrowing of 85-100% of the diameter of a vessel ( fig. 1 ). Eleven of the 83 patients who had an anginal syndrome had coronary spasm. The other basic angiographic change was relatively mild and diffuse narrowing of all coronary arteries. We interpreted this change as the normal pharmacologic response to the drug, and it occurred in all of the remaining 72 patients with anginal syndromes ( fig. 2 ) and in the seven heart transplant recipients ( fig. 3) .
The clinical and angiographic features of the 11 patients who developed coronary arterial spasm are summarized in table I. Two of these 1 1 patients (I and 11) had typical angina pectoris. Patient 1 had the onset of angina pectoris 10 months before being studied with EM. Coronary arteriography done at that time was normal; however, angina pectoris recurred with increasing frequency. Before being studied with EM, a treadmill exercise ECG showed 6 mm ST-segment elevations in leads II, III, and aVF with chest pain and Mobitz type I atrioventricular heart block. These changes occurred 2-3 minutes into the recovery period of the stress test, and they were promptly reversed by sublingual nitroglycerin. Patient 11 had the onset of angina pectoris 1 year before he was studied with EM. In the month before study, pain began to occur with less exertion and he was hospitalized for possible myocardial infarction which was not confirmed by electrocardiographic changes or abnormal cardiac enzymes. This patient did not have an exercise treadmill ECG. One (patient 7) had atypical chest pain and eight patients (2-6 and 8-10) had variant angina pectoris. Coronary spasm occurred after 0.05 mg and 0.40 mg of EM. It occurred in the right coronary artery of five patients (1-3, 8 and 10) and in the left anterior descending coronary artery of six patients (4-7, 9 and 11). Spasm occurred at sites where there was no coronary arterial narrowing in three patients (1, 5 and 7), 0-50% coronary arterial narrowing in three patients (2, 8 and 11) , and >50% coronary arterial narrowing in five patients (3, 4, 6, 9 and 10). Nine patients (1) (2) (3) (4) (5) (6) (7) 8 
